Compare AER & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | ROIV |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 20.7B |
| IPO Year | 2006 | 2021 |
| Metric | AER | ROIV |
|---|---|---|
| Price | $135.14 | $28.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $150.29 | $27.56 |
| AVG Volume (30 Days) | 1.4M | ★ 4.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.53 | $385.85 |
| P/E Ratio | $7.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $85.57 | $8.73 |
| 52 Week High | $154.94 | $30.33 |
| Indicator | AER | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 54.64 |
| Support Level | $129.85 | $26.94 |
| Resistance Level | $138.34 | N/A |
| Average True Range (ATR) | 4.30 | 1.01 |
| MACD | -1.63 | -0.26 |
| Stochastic Oscillator | 14.96 | 38.46 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.